QuickView: Eye-D and CellDetect bladder reach milestones
Two of BioLight’s important assets have recently achieved milestones. Eye-D has begun a Phase I/IIa US trial in glaucoma and a patent protecting the drug-delivery platform until 2031 has been issued. The potential of CellDetect to improve the detection of bladder cancer using cytology has been supported by interim data from a 65-patient, blinded clinical trial. Despite these advances and BioLight’s broad pipeline, its market cap is only NIS79m.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.